

### Clinical Pharmacy Program Guidelines for Lucemyra

|   |   |
|---|---|
| Program                                 | Prior Authorization- Lucemyra   |
| Medication                              | Lucemyra (lofexidine)   |
| Markets in Scope                        | Arizona, California, Colorado, Hawaii, Nevada, New Jersey, New York, New York EPP, Pennsylvania- CHIP, Rhode Island, South Carolina |
| Issue Date                              | 11/2018   |
| Pharmacy and Therapeutics Approval Date | 1/2021  |
| Effective Date                          | 3/2021  |

**1. Background:**

Lucemyra is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

**2. Coverage Criteria:**

|  |
|--|
| <p><b>A. Lucemyra</b> will be approved based on the following criteria:</p> <p>1. <b>All</b> of the following:</p> <p style="padding-left: 40px;">a. For symptoms of abrupt opioid withdrawal.</p> <p style="text-align: center;"><b>-AND-</b></p> <p style="padding-left: 40px;">b. Opioids have been discontinued.</p> <p style="text-align: center;"><b>-AND-</b></p> <p style="padding-left: 40px;">c. <b>One</b> of the following:</p> <p style="padding-left: 80px;">(1) History of failure, contraindication, or intolerance to clonidine.</p> <p style="text-align: center;"><b>-OR-</b></p> <p style="padding-left: 80px;">(2) Lucemyra was initiated in the inpatient setting.</p> <p><b>Authorization will be issued for 14 days of therapy. If Lucemyra was initiated in the inpatient setting, the total course of therapy should not exceed 14 days.</b></p> |
|--|

**3. Additional Clinical Rules:**

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place

**4. References:**

1. Lucemyra prescribing information. WorldMeds, LLC. Louisville, KY. May 2018.
2. Gowing L, Farrell M, Ali R, White J. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systemic Reviews 2016, Issue 5.

| Program               | Prior Authorization – Lucemyra   |
|-----------------------|--|
| <b>Change Control</b> |  |
| Date                  | Change   |
| 11/2018               | New program.   |
| 11/2019               | Annual review. No changes to criteria.   |
| 1/2021                | Annual review, added Additional Clinical Rules with no changes to clinical criteria. |